Pharma Focus Asia

Lonza Announces to Expand HPAPI Development and Manufacturing Capacity


Lonza announced an expansion of Highly Potent API (HPAPI) capabilities from development to commercial scale manufacturing, including formulation and delivery.


Lonza has industry-leading capability in HPAPI development and manufacturing complemented with particle engineering and specialised finished drug products for oral and parental delivery applications.

The new expansion will add two 4m3-scale, multi-purpose production lines for HPAPI manufacturing, improving Lonza's flexibility in existing production lines, helping in shorter time-to-market and accelerated approval timelines for partners.

Lonza reports that the facility will support the delivery of products from AstraZeneca portfolio under a long-term manufacturing agreement.

The HPAPI capacity expansion is expected to be operational by July 2020.


NameLonza Pharma & Biotech
ScheduleScheduled to be operational by 2020
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference